Accordingly, therapy with thrombopoietin receptor agonists (TPO-RA), labeled for immune thrombocytopenia and aplastic anemia, has shown some efficacy in thrombocytopenic MDS patients (6). This evidence concerns the gene TPO and myelodysplastic syndrome.